Longitudinal study of bone mineral density in patients with Crohn's disease

Osteoporosis is frequent in Crohn's disease. The aim of the study was to assess the rate of bone loss over time retrospectively and the influence of disease-related factors on bone loss. Twenty-nine patients (8 male), admitted for repeated bone mineral density assessments (BMD) were enrolled. BMD measured by dual energy x-ray absoptiometry was expressed in grams per square centimeter, and as sex- and age-matched Z score. The mean interval between BMD assessments was 41 months, during which period 27 patients used corticosteroids (mean dose 8.6 g) and 21 patients some form of bone protective medication. Initial Z scores at a mean age of 41 years were significantly below zero (spine –1.6 ± 1.4; femur –1.4 ± 1.4). Over time, no change in absolute BMD was observed accompanied by an improvement in Z scores. At the same time, an increase in body weight and a decrease in erythrocyte sedimentation rate (ESR) was observed. Multilinear regression analysis demonstrated change in ESR as independent predictor for change in femoral Z score. In conclusion, low BMD is frequent in Crohn's disease, but decline of BMD over time was not found, despite ongoing use of corticosteroids.     

Normative bone mineral density values in Filipino women

Objective: To obtain reference values of bone mineral density (BMD) for Filipino women in order to make a population‐specific diagnosis of osteoporosis. Method: Sudy design: Cross‐sectional. Setting: Osteoporosis Unit, Joint and Bone Center, Section of Rheumatology and Clinical Immunology, Department of Medicine, University of Santo Tomas Hospital, Manila, Philippines. Participants: 442 healthy Filipino women volunteers recruited from the outpatient department, Rheumatology and Clinical Immunology Clinic of the University of Santo Tomas Hospital and from within the University of Santo Tomas campus. Subjects with known underlying illness or conditions or intake of drugs that predispose to osteoporosis were excluded from the study. Intervention: Bone mineral density (BMD) measurements, expressed in grams per square centimenter of the lumbar spine, non‐dominant femur and non‐dominant forearm were done in 442 consecutive healthy Filipino women using the LUNAR DPX‐IQ machine. Results: Means and standard deviations of BMD measurements at each site were calculated using Kwikstat software Version 3.6, Release 7. Results were grouped in decades to serve as reference per decade. Conclusion: Bone mineral density measurements of these 442 healthy Filipino women may serve as an initial reference guide for the diagnosis of osteoporosis in Filipino women.     

绝经后妇女腰椎和髋部骨密度变化的临床研究及意义

目的研究绝经后妇女骨密度（ＢＭＤ）变化情况及与骨质疏松的关系。方法用双能Ｘ线骨密度测量仪（ＤＥＸＡ）检测１４４名绝经后妇女腰椎和髋部的ＢＭＤ。结果妇女绝经后骨矿物含量随增龄逐渐下降，髋部各区域的骨丢失高于腰椎，以Ｗａｒｄ三角最明显，其顺序为Ｗａｒｄ三角＞股骨颈＞股骨粗隆＞腰椎２～４（Ｌ２～Ｌ４）。绝经年限与腰椎和髋部的ＢＭＤ呈明显负相关，在绝经１０年内呈线性下降，以后下降相对缓慢。结论妇女绝经后松质骨骨量丢失明显，在临床检测中，髋部骨密度的测量对妇女绝经后骨质疏松早期诊断及预防骨折有重要意义。     

青岛地区成年女性多部位骨密度数据库建立

目的确立青岛地区正常成年女性骨密度(BM D)正常参考范围,建立诊断成年女性骨质疏松症(OP)的多骨骼部位BM D参考值。方法用Cha llenge双能X线骨密度仪测量868例25~83岁女性腰椎(L2~L4)侧位和左侧髋部(股骨颈、大转子、W ards三角区)6个骨骼区域的BM D,用8种回归模型拟合健康成年女性BM D随年龄的变化,找出最佳拟合方程建立数据库。结果①6个骨骼区域BM D随年龄变化,不同部位骨峰值出现时间不同,腰椎在25~29岁,髋部在40~44岁。②拟合曲线的决定系数(R2)为0.21±0.09(P<0.01)。结论女性45岁后骨丢失加速,应开始监测BM D。本数据库建立为青岛地区成年女性诊断OP提供了可靠的参考标准。     

435名女性体检者血清铁蛋白与骨密度的相关性

目的了解正常女性随年龄增长体内铁含量与骨密度变化的关系,分析铁含量与骨密度的相关性。方法收集2011年1月至2012年12月在苏州大学附属第二医院435名22~80岁体检女性血清铁蛋白和骨密度数据。采用电化学发光法检测血清铁蛋白,采用双能X线吸收仪测定骨密度。按每5岁为1个年龄段分组,分别统计各组受试者血清铁蛋白和不同部位骨密度的平均值,观察血清铁蛋白、骨密度随年龄变化的情况。将血清铁蛋白按5等分法分类,运用非条件Logistic回归法,分析随血清铁蛋白升高,发生骨量减少风险的变化。采用多元逐步回归分析、偏相关分析法,了解正常女性血清铁蛋白变化与骨密度的相关性。结果女性血清铁蛋白随年龄增加而增加,骨密度随年龄增加而下降,两者变化趋势在围绝经期、绝经期变化显著。骨量减少组(-2.5T值-1.0)血清铁蛋白平均值显著高于骨量正常组(P0.001),骨质疏松组(T值≤-2.5)血清铁蛋白平均值显著高于骨量减少组(P0.01)和骨量正常组(P0.001)。校正混杂因素后,血清铁蛋白按5等分法分组,非条件Logistic回归显示血清铁蛋白最高组与最低组相比,股骨颈和腰椎发生骨量减少的OR值(95%CI)分别为2.82(1.25~6.38)和2.04(0.92~4.51),提示随血清铁蛋白增加,骨量减少发生的风险增加。多元逐步回归分析显示,与骨密度变化相关指标为年龄、体重、血清铁蛋白和体重指数(BMI),校正年龄、体重、BMI、C反应蛋白(CRP)等混杂因素后,血清铁蛋白与不同部位骨密度均呈显著负相关(P0.05)。结论随着年龄增长,女性血清铁蛋白逐渐升高、骨密度逐渐下降,二者呈显著负相关。血清铁蛋白增高时,骨量减少、骨质疏松发生率升高。     

河北地区健康女性不同年龄不同部位骨密度调查分析

目的分析河北地区不同年龄不同部位健康女性的骨密度变化。方法将河北地区923名健康女性,年龄20～80岁,每10岁为1组,分为6组,所有受试对象均记录年龄、身高、体重、体重指数（BMI）、女性绝经年限,同时测定腰椎2_4、股骨颈、ward＇s三角、大转子、转子间的骨密度（BMD）;计算各组骨质疏松发生情况,找出各部位骨峰值,分析年龄、BMI与各部位骨密度的关系,同时分析50岁以上女性年龄、BMI、绝经年限与骨密度的相关性。结果40～49岁骨质疏松（OP）发现率为11．72％,50～59岁为31．54％,60～69岁为63．42％,70～79岁为79．84％,骨峰值出现在30—39岁,30—39岁不同部位骨密度均明显高于其他年龄组（P〈0．05）;20～29岁与40～49岁各部位BMD无明显差别（P〉0．05）;其他各年龄组股骨颈、ward＇s三角、大转子、转子间骨密度两两比较均有显著差别（P〈0．05）;肥胖组的L2-4,ward＇s三角区BMD均明显高于正常体重组与超重组（P〈0．05）,但后两组无明显差别（P〉0．05）;肥胖组的股骨颈、大转子、转子间BMD均明显高于正常体重组（P〈0．05）,但肥胖组与超重组,正常体重组与超重组相比以上部位BMD无明显差别（P〉0．05）,相关分析表明：各部位骨密度与年龄呈负相关,与BMI呈正相关,50岁以上女性同时发现绝经年限与各部位骨密度呈负相关,但相关性以年龄最好。结论建立了河北地区健康女性不同年龄不同部位骨密度的数据库,为骨质疏松预防、诊治提供参考数据。     

雷奈酸锶对绝经后骨质疏松症妇女骨密度的影响

目的观察雷奈酸锶(SR)对绝经后骨质疏松症妇女骨密度的影响。方法采用随机、双盲、安慰剂对照研究,对36例绝经后妇女分为试验组(n=18)和安慰剂组(n=18),分别给予SR 2g/d及安慰剂,共12个月。分别在用药前、用药6个月、用药12个月测定受试者的骨密度。结果与安慰剂组相比,使用SR 6个月后,SR组腰椎的骨密度增加1.98%,安慰剂组增加1.15%,两组比较差异无显著性(P0.05),SR组总髋部的骨密度增加2.22%,安慰剂组增加0.20%,两组比较差异具有显著性(P0.05);使用SR 12个月后,SR组腰椎的骨密度增加4.08%,安慰剂组降低0.53%,两组比较差异具有极显著性(P0.01),SR组总髋部的骨密度增加3.17%,安慰剂组降低0.46%,两组比较差异具有极显著性(P0.01)。共有4例提前终止研究(SR组2例,安慰剂组2例)。结论 SR能增加绝经后骨质疏松症妇女骨密度,服用顺应性好,安全。     

Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: a randomized controlled trial

Melatonin is known for its regulation of circadian rhythm. Recently, studies have shown that melatonin may have a positive effect on the skeleton. By increasing age, the melatonin levels decrease, which may lead to a further imbalanced bone remodeling. We aimed to investigate whether treatment with melatonin could improve bone mass and integrity in humans. In a double‐blind RCT, we randomized 81 postmenopausal osteopenic women to 1‐yr nightly treatment with melatonin 1 mg (N = 20), 3 mg (N = 20), or placebo (N = 41). At baseline and after 1‐yr treatment, we measured bone mineral density (BMD) by dual X‐ray absorptiometry, quantitative computed tomography (QCT), and high‐resolution peripheral QCT (HR‐pQCT) and determined calciotropic hormones and bone markers. Mean age of the study subjects was 63 (range 56–73) yr. Compared to placebo, femoral neck BMD increased by 1.4% in response to melatonin (P < 0.05) in a dose‐dependent manner (P < 0.01), as BMD increased by 0.5% in the 1 mg/day group (P = 0.55) and by 2.3% (P < 0.01) in the 3 mg/day group. In the melatonin group, trabecular thickness in tibia increased by 2.2% (P = 0.04), and volumetric bone mineral density (vBMD) in the spine, by 3.6% (P = 0.04) in the 3 mg/day. Treatment did not significantly affect BMD at other sites or levels of bone turnover markers; however, 24‐hr urinary calcium was decreased in response to melatonin by 12.2% (P = 0.02). In conclusion, 1‐yr treatment with melatonin increased BMD at femoral neck in a dose‐dependent manner, while high‐dose melatonin increased vBMD in the spine. Further studies are needed to assess the mechanisms of action and whether the positive effect of nighttime melatonin will protect against fractures.     

中青年甲状腺功能亢进患者骨密度特点

目的分析中青年甲状腺功能亢进(甲亢)患者骨密度特点及其与病程、病情严重程度的关系。方法使用双能X线骨密度仪分别测定340例中青年甲亢患者及160名年龄匹配的正常对照者的前臂、腰椎及股骨颈骨密度,用化学发光法测定甲亢患者游离三碘甲腺原氨酸(FT3)、游离甲状腺激素(FT4)及促甲状腺激素(TSH),用自动生化仪检测血清钙(Ca)、血清磷(P)、碱性磷酸酶(ALP),比较2组间骨密度及Ca、P、ALP的差异。根据国际临床骨密度学会(ISCD)和国际骨质疏松基金会(IOF)对中青年骨质疏松诊断的不同定义分别将甲亢患者分为骨量正常组(ON1)和骨质疏松组(OP1)、骨量正常组(ON2)、骨量减少组(OD2)、骨质疏松组(OP2),比较使用2种诊断方法得出的骨质疏松检出率,比较各组甲状腺激素(TH)及TSH的差异。结果与正常对照组相比,甲亢患者桡骨全部、腰椎L2-4及股骨颈骨密度均明显降低(均P0.05)。根据ISCD定义得出的骨质疏松检出率为46.8%,根据IOF定义得出的骨质疏松检出率为27.1%,前臂较腰椎、股骨颈骨密度降低更明显。甲亢患者骨质疏松组较骨量正常组的FT3、FT4明显升高(P0.05),TSH明显降低(P0.05)。多元线性回归分析显示桡骨骨密度与FT4、Ca呈负相关,与TSH呈正相关。结论中青年甲亢患者骨质疏松患病率高,骨量丢失较明显的部位为桡骨,过量甲状腺激素及低TSH均可导致骨代谢紊乱。     

Effects of physical training on bone mineral density in fertile women with idiopathic osteoporosis

The aim of this study was to investigate whether moderate physical training can improve the bone mineral density (BMD) in women with idiopathic osteoporosis. Ten pre-menopausal women aged 24–44 years diagnosed with idiopathic osteoporosis were included in the study. The physical training program consisted of three fast 30-min walks plus one or two sessions of 1-h training per week during 1 year at a training centre separate from the hospital. All patients were given supplements of vitamin D and calcium. Bone mineral density was measured in the femoral neck area and the lumbar spine by dual energy X-ray absorptiometry. The measurements were performed at baseline and after 12 months of training and compared with the measurements at the time of diagnosis, 1–3 years before the study. Eight women fulfilled the 12-month training period, and their mean (SD) BMD at start was 0.88 (0.08) g/cm² in the spine and 0.76 (0.13) g/cm² in the femoral neck. The mean spine BMD increase was 0.031 g/cm² (3.5%) after 1 year of training, which was significant (Wilcoxon’s non-parametric test, p = 0.018). The mean increment in BMD in the femoral neck was insignificant, 0.007 g/cm² (0.9%) after the intervention (p = 0.74). However, the bone loss during the 1- to 3-year period from diagnosis to study start was, on average, 0.045 g/cm² or 5.0% in the femoral neck (p = 0.042), thus indicating a positive indirect effect of the intervention. There is no evidence-based therapy for women with idiopathic osteoporosis. It is therefore of importance to elucidate the impact of moderate physical activity in this group of patients. A 1-year training program was sufficient to induce a small but significant change in the spine BMD.     

苏州地区1931名健康成人腰椎骨密度调查分析

目的了解苏州地区正常成年人群腰椎骨密度(BMD)的正常参考值及其变化规律。方法应用双能X线骨密度仪,对1931名成年健康男女进行腰椎(L_(1-4))骨密度测量,并将所得结果标准化处理后进行统计学分析。结果①男性腰椎(L_(1-4))BMD值在20～29岁达到峰值,女性在30～39岁达到峰值,女性较男性晚10年;②男性BMD值在30岁以后逐渐降低,但无明显加速丢失期;女性BMD在40岁以后开始丢失,且存在迅速丢失现象;苏州地区健康成年人腰椎BMD峰值:男性为(1.084±0.135)g/cm~2,女性为(1.096±0.119)g/cm~2,男性腰椎BMD峰值略低于女性。结论初步明确苏州地区健康人群腰椎BMD峰值,发现不同性别和不同年龄组人群骨密度的变化规律及其差异,为本地区骨质疏松的预防和诊治提供了有用的信息。     

强直性脊柱炎患者骨密度随年龄的变化

目的 采用双能X线吸收法测量强直性脊柱炎患者(AS)不同部位的骨密度(BMD),探讨其与年龄变化的关系,为临床防治AS患者BMD降低提供参考.方法 选取门诊50例符合纽约诊断标准的AS患者,按年龄≤40岁、年龄＞ 40岁分为两组,分别检测其侧位腰椎(L1-L4)、股骨颈、髋关节BMD,以T值≤-1.0定义为BMD降低,包括骨量减少(-2.5＜T＜-1.0)与骨质疏松(T≤-2.5).结果 两组AS患者出现BMD降低的比例均高于正常人,且年龄＞ 40岁组其腰椎BMD减少的比例高于年龄≤40岁组(P＜0.05),而其腰椎平均T值低于年龄≤40岁组(P＜0.05),在股骨颈测得的BMD、骨质疏松比例两组无明显差异(P＞0.05).结论 AS患者早期即可出现骨量减少甚至骨质疏松,随着年龄的增长其侧位腰椎BMD降低明显,骨折风险增大.临床上应当提高对AS合并骨质疏松的警惕,及时予补钙等治疗,提高患者的生活质量.     

Correlation between bone mineral density of different sites and lumbar disc degeneration in postmenopausal women

Osteoporosis and lumbar disc degeneration (LDD) have been common causes that make increasing patients suffer from different degrees of low back pain. At present, whether osteoporosis degenerates or protects disc is still controversial, and the correlation between hip bone mineral density (BMD) and LDD still remains unclear. Our study aims to analyze the correlation between BMD of different sites and LDD in postmenopausal women, and explore the potential pathophysiological mechanism of them.One hundred ninety-five postmenopausal female patients were enrolled and divided into osteoporosis, osteopenia, and normal bone mass groups. Their BMD and lumbar spine magnetic resonance imaging were retrospectively analyzed. Two spine surgeons were selected to assess LDD according to Pfirrmann grading system.Based on lumbar BMD, LDD of normal bone mass group was more severe than the other 2 groups in L1/2 and L2/3 segments (P < .05). Based on hip BMD, LDD of each disc from L1/2 to L5/S1 had no significant difference among the 3 groups (P > .05). Lumbar BMD (L1-L4) was positively correlated with corresponding degree of LDD (L1/2-L4/5) (P < .05), whereas there was no correlation between hip BMD and degree of LDD (P = .328).There is a positive correlation between lumbar BMD and LDD in postmenopausal women, which is more obvious in the upper lumbar spinal segments (L1, L2). However, there is no correlation between hip BMD and LDD, suggesting that in postmenopausal women with lumbar degenerative disease, hip BMD is more suitable for the diagnosis of osteoporosis.     

Depressive symptoms and rates of bone loss at the hip in older women

OBJECTIVES: To ascertain whether depressive symptoms are associated with increased rates of bone loss at the hip. DESIGN: Population-based prospective cohort study. SETTING: Four clinical centers in the United States. PARTICIPANTS: Four thousand one hundred seventy-seven community-dwelling women, aged 69 and older, enrolled in the Study of Osteoporotic Fractures. MEASUREMENTS: Depressive symptoms were assessed using the Geriatric Depression Scale (GDS). Subjects were categorized as depressed if their GDS score was 6 or greater at the fourth examination. Bone mineral density (BMD) at the hip was measured using dual-energy x-ray absorptiometry at the fourth and sixth examinations (average 4.4 years between examinations). Use of antidepressant medications was assessed by interview and verified from medication containers at the fourth and sixth examinations of the Study of Osteoporotic Fractures. A computerized dictionary was used to categorize type of medication. RESULTS: In age-adjusted models, mean total hip BMD decreased 0.69%/year in 3,977 women with a GDS score of less than 6, compared with 0.96%/year in 200 women with a GDS score of 6 or greater (P<.01). Results were not substantially altered when adjusted for potential confounders and when users of antidepressants were excluded from the analysis. CONCLUSION: Depression, as defined by a GDS score of 6 or greater, was associated with an increased rate of bone loss at the hip in this cohort of older women. Clinicians should be aware of a possible increased rate of bone loss in older, depressed women.     

健康和骨折女性骨矿密度及其骨折阈值的测定

目的初步确定天津市女性骨矿密度（ＢＭＤ）正常参考值范围，探讨骨质疏松的诊断标准及骨折危险阈值。方法用双能Ｘ线吸收法（ＤＥＸＡ）对４５２例健康女性和５５例绝经后骨折患者ＢＭＤ进行测定。结果腰椎２～４、股骨和全身ＢＭＤ峰值分别在３０～３９、２０～２９和４０～４９岁。ＢＭＤ与年龄、绝经年限呈负相关（均为Ｐ＜０．０１），以绝经后最初５年的降低率最高；ＢＭＤ与身高呈正相关，６０岁以上妇女的体重和脂肪量与各部位ＢＭＤ呈正相关（Ｐ＜０．０５或０．０１）。以２０～４０岁女性腰椎ＢＭＤ均值减２．５标准差（ｓ）为界限值（０．８３ｇ／ｃｍ２），５５例骨折患者中４６例（８３．６％）腰椎ＢＭＤ低于界限值。结论该界限值作为女性骨质疏松诊断标准和脊椎骨折危险阈值可能较为合理。     

Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia

Summary.  Osteoporosis in adult males is an under-recognized problem. Patients with haemophilia have several predisposing factors for developing decreased bone mineral density (BMD) including prolonged periods of immobility, reduced weight bearing and co-morbidities associated with bone loss. To establish prevalence and risk factors associated with decreased BMD in patients with haemophilia. Adults with moderate or severe haemophilia A or B underwent dual-energy X-ray absorptiometry (DXA). BMD was correlated to laboratory values, joint mobility measurements and physical activity questionnaires. Thirty patients completed evaluations. The median age was 41.5 years (range 18–61). Median lowest T-score by DXA was −1.7 (range: −5.8 to +0.6), with the femoral neck being the site of the lowest T-scores. Based on World Health Organization criteria, 70% of patients had decreased BMD. Twenty-seven per cent of the participants ( n  = 8) had osteoporosis and 43% ( n  = 13) had osteopenia. Variables associated with increased bone loss included lower serum 25-hydroxyvitamin D levels ( P  = 0.03), lower body mass index ( P  = 0.047), lower activity scores ( P  = 0.02), decreased joint range of motion ( P  = 0.046), HIV ( P  = 0.03), HCV ( P  = 0.02), history of inhibitor ( P  = 0.01) and age ( P  = 0.03). Adults with haemophilia are at increased risk for developing osteoporosis. A history of HCV and HIV infections, decreased joint range-of-motion, decreased activity levels, history of an inhibitor and low body weight predict bone loss and suggest a population to target for screening. A high prevalence of vitamin D insufficiency was observed. Future studies should investigate interventions, including vitamin D supplementation, to prevent bone loss and fractures for this at-risk population.     

Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover

BACKGROUND: Loop diuretics (LD) are widely used in the treatment of cardiovascular diseases and disorders with fluid accumulation. LD are known to increase renal calcium losses and may thereby affect calcium homeostasis and bone metabolism. OBJECTIVE: We studied to what extent long-term treatment with LD affects calcium homeostasis and bone metabolism. DESIGN AND SUBJECTS: In a cross-sectional design we compared 140 postmenopausal women treated with a LD for more than 2 years with 140 age-matched women not in diuretic therapy. RESULTS: Treatment with LD was associated with significantly increased urinary calcium, plasma parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D levels. Per 40 mg day(-1) of furosemide, urinary calcium was increased by 17% (P < 0.05) and plasma PTH levels were increased by 28% (P = 0.04). Users of LD had a 17% higher body weight (P < 0.001) compared with nonusers. This was due to a 32% higher fat mass (P < 0.001) and a 6% higher lean tissue mass (P < 0.001). Moreover, users of LD had a higher bone mineral density (BMD) at the spine (+7.5%, P < 0.001), hip (+4.8%, P = 0.004), forearm (+3.7%, P = 0.01) and whole body (+2.5%, P = 0.06). However, after adjustment for body weight differences, BMD did not differ between groups. Nevertheless, duration of LD treatment was positively associated with BMD at the spine (P = 0.03) and whole body (P < 0.05). BMD at the spine increases by 0.3% per 1 year of treatment. CONCLUSIONS: The increased renal calcium losses in users of LD are compensated for by a PTH-dependent increase in 1,25(OH)(2)D levels. Thereby calcium balance remains neutral without major effects on bone metabolism.     

武汉地区11 559名受试者跟骨骨密度检测结果分析

目的调查武汉地区不同年龄人群骨质疏松症的患病情况,为武汉地区骨质疏松症的防治提供依据。方法采用美国LUNAR PIXI骨密度检测仪,对2004年1月至2008年12月在武汉市江汉区初次行骨密度检测的11559名体检者(年龄20～99岁,男6434名,女5125名)进行右侧足跟部骨密度检查,受试者按年龄、性别和骨量情况分组,计算各组受试者的BMD值以及骨量减少和骨质疏松的发病率。结果骨量正常者的比例从20～岁组的80.5%降至80～岁组的31%。在年龄60岁的人群中,女性骨量正常者的比例较同年龄组的男性明显减少,60～、70～和80～岁组女性骨量正常的比例为36.5%、26.7%和15%,相应年龄组男性骨量正常的比例为55.6%、46.2%和38.2%。骨量减少和骨质疏松者的比例从20～岁组的18.7%和0.8%升至80～岁组的40.3%和28.7%,骨量减少的发生率从50～岁起明显升高,骨质疏松的发生率从60～岁起明显增高。在年龄60岁的人群中,女性骨量减少和骨质疏松者的比例较同年龄组男性明显增加。在60～、70～和80～岁组女性骨量减少的比例是男性的1.26、1.16和1.39倍,骨质疏松者的比例为男性的2.48、1.92倍和1.36倍。在骨量正常、骨量减少和骨质疏松组中,男性与女性受试者BMD值的差异均有统计学意义,男性BMD值均高于女性(均P0.05)。结论骨量正常者比例在20～岁组最高,并随年龄的增长而下降。骨量减少和骨质疏松者比例在20～岁组最低,并随年龄增长而升高。男性骨密度均较同年龄组女性高,女性比男性更易患骨量减少和骨质疏松症。